today , page-31

Agree OkayPublic, another great presentation highlighting the significant potential of our a company and how our drugs compare favourably against those currently in the market.
re 1102
"Tysabri sells about $1.6 billion a year. Its regarded as the most potent drug today for treating relapsing remitting Ms. Those familiar with the Ms market might know that there is a series of new oral drugs that have entered the market. But the view is none of those have been able to reach the efficacy of Tysabri."
"We are contemplating a drug that would be as potent as Tysabri, potentially safer, so avoiding the activation of the Jc virus and that viral infection of the brain. But also cheaper to manufacture and more conveniently dosed. Subcutaneously administered once weekly, maybe less often, versus an iv infusion."
"Chronic toxicology study that's just completed. We are waiting for a readout on that study that's going to come through this month."

re 1103
"we had one patient who's igf-1 levels were reduced by over 50%. So we are very encouraged by this data. We think with that level of serum igf-1 reduction we already believe we've got a drug that would be useful as a therapy for treating patients with the disease."

re Stem Cell Mobilisation
"Because we are only applying the drug for 1 week administration we already have got, we believe, the safety experience to commercialise this drug ; so to take it all the way through to phase 3 clinical trials, based on what we've shown in our Ms program where we dosed for 2 months.
So we think it will be very quick cost effective program."

re Company
" Multiple shots on goal, so de-risked in terms of project outcomes and most importantly we have got projects with significant commercial potential."